Vernalis and Servier's next tie-up: two years, €2mm up front
Servier SA and Vernalis PLC have signed their fourth collaboration focused on the development of new cancer drugs.
- Drug Discovery Technologies
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.